Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Liu, Lixiong, Hong, Xiaoping, Liu, Dongzhou, Cheng, Zeneng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645831/
https://www.ncbi.nlm.nih.gov/pubmed/34880764
http://dx.doi.org/10.3389/fphar.2021.782385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645831/
https://www.ncbi.nlm.nih.gov/pubmed/34880764
http://dx.doi.org/10.3389/fphar.2021.782385

Ejemplares similares